Author:
Gusev Е. I.,Demina Т. L.,Boiko А. N.,Buglak А. V.,Belyaeva I. А.,Smirnova N. F.,Alekseeva Т. G.,Pashchenkov М. V.,Skurkovich В.,Kelly D.,Skurkovic S. V.
Abstract
For treating active forms of secondarily-progressing multiple sclerosis a preliminary clinical trial was performed by two courses: antibody-to-cytokine course (INT, INT and TNF) and cyclosporin А-course (sandimmun). Data of preliminary test of antibodies to cytokines evidence to possibility of performing further clinical trials "antibodies to INT and to TNF (to a lesser degree)" during active forms of progressive MS. Were obtained the results, evidencing to a possible use of sandimmun in constantly progressive forms of secondarily progressing disease, when favourable clinical effect coincided with supression of cytokine IL-2 production and lowering of activeness of immunocytes.
Subject
Literature and Literary Theory,History,Cultural Studies
Reference18 articles.
1. Гусев Е.И., Демина Т.Л., Бойко А.Н., Татаринова М.Ю. // Журн. невропатол. и психиатр.—1992.—№ 2.—С. 14—18.
2. Arnason B.G.W., Reder А.Т. // Clin. Neuropharmacol.— 1994—Vol.17 .—P.495—547.
3. Goodkin D.E. // West J. Med.—1994.—Vol.161.— P.292—298.
4. Gusev E.I., Demina T.L., Boiko A.N., Pinegin B.V. // J. Neurol.—1994.—Vol.241—P.500—510.
5. Gusev E.I., Demina T.L., Boiko A.N., Favorova 0.0. In: Milonas I (ed). Proceedings of the 10th ECTRIMS Congress.—University Studio Press, Thessaloniki, Greece, 1995.—P.201—203.